Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) Director Dennis Langer sold 23,766 shares of the stock in a transaction dated Wednesday, November 16th. The shares were sold at an average price of $3.52, for a total transaction of $83,656.32. Following the completion of the transaction, the director now directly owns 43,595 shares of the company’s stock, valued at $153,454.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded down 10.38% on Friday, hitting $3.80. 406,863 shares of the stock were exchanged. Dicerna Pharmaceuticals Inc. has a one year low of $2.69 and a one year high of $15.93. The firm’s 50-day moving average is $4.03 and its 200-day moving average is $3.63. The company’s market cap is $78.86 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last posted its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.17. The firm had revenue of $162 million for the quarter. On average, equities analysts forecast that Dicerna Pharmaceuticals Inc. will post ($2.95) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of DRNA. FMR LLC raised its stake in shares of Dicerna Pharmaceuticals by 0.4% in the second quarter. FMR LLC now owns 3,108,916 shares of the biopharmaceutical company’s stock worth $9,327,000 after buying an additional 11,719 shares in the last quarter. Oxford Asset Management increased its stake in Dicerna Pharmaceuticals by 109.3% in the second quarter. Oxford Asset Management now owns 286,413 shares of the biopharmaceutical company’s stock worth $859,000 after buying an additional 149,560 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Dicerna Pharmaceuticals during the first quarter worth approximately $343,000. Paloma Partners Management Co acquired a new stake in Dicerna Pharmaceuticals during the second quarter worth approximately $183,000. Finally, A.R.T. Advisors LLC purchased a new stake in Dicerna Pharmaceuticals during the second quarter worth about $170,000. 62.34% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages have issued reports on DRNA. Leerink Swann reaffirmed a “buy” rating and issued a $8.00 target price on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 8th. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 10th. Chardan Capital dropped their target price on shares of Dicerna Pharmaceuticals from $4.00 to $3.50 and set a “neutral” rating for the company in a report on Monday, August 8th. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Friday, August 5th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 target price on shares of Dicerna Pharmaceuticals in a report on Wednesday, September 28th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Dicerna Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $9.85.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

5 Day Chart for NASDAQ:DRNA

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.